Trial Profile

A proof of concept, single dose study of oral Leptin for type 1 diabetic patients

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Leptin (Primary)
Indications Type 1 diabetes mellitus
Focus First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept

Most Recent Events

29 Jun 2021 Results assessing the short-term effects of a single ORMD-0701 dose (3 mg leptin) administered to fasting patients with type 1 diabetes, presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
23 Dec 2020 Status changed from planning to recruiting, according to an Oramed Pharmaceutical media release.
23 Dec 2020 According to an Oramed Pharmaceutical media release, this study is approved by the Israel's Ministry of Health.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com